Investors & Media

Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen

– Results from interim analysis expected by mid-2022 – NDA filing to potentially follow by year-end 2022 CARLSBAD, Calif. , July 29, 2021 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has completed enrollment of

Read more
You are now leaving to visit